Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019

Bibliographic Data

ID15807327
AuthorsLisa Clemans-Cope (0000-0002-8081-6952, Urban Institute, corresponding author), Marni Epstein (Lake County), Jessica S Banthin (Urban Institute), Jessica Banthin (Health Policy Center, The Urban Institute, Washington, DC), Aaron S Kesselheim (0000-0002-8867-2666, Harvard University), Thomas J Hwang (0000-0003-0717-1497, Brigham and Women's Hospital)
Year2023
Volume4
Issue1
Pagese225012-e225012
Publication date2023-01-13
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueJAMA Health Forum (JOURNAL)
Journal identifiersISSN: 2689-0186 • E-ISSN: 2689-0186
PublisherAmerican Medical Association (PUBLISHER • US)
DOI10.1001/jamahealthforum.2022.5012
PMID36637815
OpenAlexW4315928508
LanguageEN
Citations received1
References cited9

In this cross-sectional study of 18 top-selling brand-name drugs, excluding 1 anomaly, Medicaid average net prices declined from 2015 to 2019. Simultaneously, for non-Medicaid payers, net price increased more than previously published marketwide growth rates, raising the importance of restraining drug price growth in non-Medicaid markets. Rigorous and transparent methods to estimate Medicaid discounts are imperative to understand patterns in Medicaid and non-Medicaid prices and develop policies that better align drug prices with clinical benefits

Actuarial science · Business · Economic growth · Economics · Health care · Medicaid · Medical prescription · Prescription drug · Sample (material · Health Systems, Economic Evaluations, Quality of Life · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare · Pharmacology

Tools

Open DOIOpen Access